| Year |
Citation |
Score |
| 2024 |
Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG. Negative allosteric modulation of cannabinoid CB receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. Biorxiv : the Preprint Server For Biology. PMID 38260598 DOI: 10.1101/2024.01.06.574477 |
0.316 |
|
| 2023 |
Guenther KG, Xu Z, Romero J, Hillard CJ, Mackie K, Hohmann AG. Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain. Neuropharmacology. 109601. PMID 37286073 DOI: 10.1016/j.neuropharm.2023.109601 |
0.36 |
|
| 2021 |
Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain. PMID 35001054 DOI: 10.1097/j.pain.0000000000002502 |
0.3 |
|
| 2020 |
Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG. The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology. 886: 173544. PMID 32896549 DOI: 10.1016/J.Ejphar.2020.173544 |
0.397 |
|
| 2020 |
Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Frontiers in Molecular Neuroscience. 13: 54. PMID 32410959 DOI: 10.3389/Fnmol.2020.00054 |
0.407 |
|
| 2019 |
Garai S, Kulkarni PM, Schaffer PC, Leo L, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, ... ... Hohmann A, et al. Application of Fluorine- And Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of CB1 Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry. PMID 31756109 DOI: 10.1021/Acs.Jmedchem.9B01142 |
0.386 |
|
| 2019 |
Slivicki RA, Mali SS, Hohmann AG. Voluntary exercise reduces both chemotherapy-induced neuropathic nociception and deficits in hippocampal cellular proliferation in a mouse model of paclitaxel-induced peripheral neuropathy. Neurobiology of Pain (Cambridge, Mass.). 6: 100035. PMID 31528755 DOI: 10.1016/j.ynpai.2019.100035 |
0.399 |
|
| 2019 |
Ferris CF, Nodine S, Pottala T, Cai X, Knox TM, Fofana FH, Kim S, Kulkarni P, Crystal JD, Hohmann AG. Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats. Neurobiology of Pain (Cambridge, Mass.). 6: 100034. PMID 31223138 DOI: 10.1016/J.Ynpai.2019.100034 |
0.381 |
|
| 2019 |
Slivicki RA, Xu Z, Mali SS, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance, physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacological Research. PMID 30739035 DOI: 10.1016/j.phrs.2019.02.002 |
0.385 |
|
| 2018 |
Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. Molecular Pharmacology. PMID 30504240 DOI: 10.1124/Mol.118.113233 |
0.484 |
|
| 2018 |
Slivicki RA, Saberi SA, Iyer V, Vemuri K, Makriyannis A, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit. The Journal of Pharmacology and Experimental Therapeutics. PMID 30275151 DOI: 10.1124/Jpet.118.252288 |
0.43 |
|
| 2018 |
Liu Y, Ji L, Eno M, Kudalkar S, Li A, Schimpgen M, Benchama O, Morales P, Xu S, Hurst DP, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis D, ... ... Hohmann A, et al. (R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry. PMID 30196704 DOI: 10.1021/Acs.Jmedchem.8B00611 |
0.331 |
|
| 2018 |
Lee WH, Carey LM, Li LL, Xu Z, Lai YY, Courtney MJ, Hohmann A. [EXPRESS] ZLc002, a putative small molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Molecular Pain. 1744806918801224. PMID 30157705 DOI: 10.1177/1744806918801224 |
0.301 |
|
| 2018 |
Lee WH, Li LL, Chawla A, Hudmon A, Lai YY, Courtney MJ, Hohmann AG. Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice. Pain. PMID 29319606 DOI: 10.1097/J.Pain.0000000000001152 |
0.423 |
|
| 2017 |
Lin X, Dhopeshwarkar AS, Huibregtse M, Mackie K, Hohmann AG. The slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence. Molecular Pharmacology. PMID 29192123 DOI: 10.1124/Mol.117.109355 |
0.417 |
|
| 2017 |
Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biological Psychiatry. PMID 28823711 DOI: 10.1016/J.Biopsych.2017.06.032 |
0.456 |
|
| 2017 |
Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. PMID 28625720 DOI: 10.1016/J.Neuropharm.2017.06.015 |
0.373 |
|
| 2017 |
Li AL, Carey LM, Mackie K, Hohmann AG. The cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. The Journal of Pharmacology and Experimental Therapeutics. PMID 28592614 DOI: 10.1124/Jpet.117.241901 |
0.471 |
|
| 2017 |
Carey LM, Gutierrez T, Deng L, Lee WH, Mackie K, Hohmann AG. Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice. Scientific Reports. 7: 944. PMID 28428628 DOI: 10.1038/s41598-017-01062-2 |
0.403 |
|
| 2017 |
Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience. PMID 28285942 DOI: 10.1016/j.neuroscience.2017.02.055 |
0.327 |
|
| 2016 |
Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG. Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. Pharmacological Research. PMID 27773824 DOI: 10.1016/J.Phrs.2016.10.007 |
0.441 |
|
| 2016 |
Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase. Molecular Pain. 12. PMID 27178246 DOI: 10.1177/1744806916649192 |
0.435 |
|
| 2016 |
Slivicki RA, Ali YO, Lu HC, Hohmann AG. Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo. Plos One. 11: e0147620. PMID 26808812 DOI: 10.1371/Journal.Pone.0147620 |
0.313 |
|
| 2015 |
Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. PMID 26071110 DOI: 10.1016/J.Neuropharm.2015.05.038 |
0.385 |
|
| 2015 |
Marcus DJ, Zee M, Hughes A, Yuill MB, Hohmann AG, Mackie K, Guindon J, Morgan DJ. Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase. Molecular Pain. 11: 34. PMID 26065412 DOI: 10.1186/s12990-015-0031-4 |
0.43 |
|
| 2015 |
Deng L, Cornett BL, Mackie K, Hohmann AG. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. Molecular Pharmacology. 88: 64-74. PMID 25904556 DOI: 10.1124/mol.115.098483 |
0.45 |
|
| 2015 |
Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biological Psychiatry. 77: 475-87. PMID 24853387 DOI: 10.1016/j.biopsych.2014.04.009 |
0.443 |
|
| 2014 |
Piomelli D, Hohmann AG, Seybold V, Hammock BD. A lipid gate for the peripheral control of pain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15184-91. PMID 25392487 DOI: 10.1523/Jneurosci.3475-14.2014 |
0.412 |
|
| 2014 |
Guindon J, Deng L, Fan B, Wager-Miller J, Hohmann AG. Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status. Molecular Pain. 10: 56. PMID 25189223 DOI: 10.1186/1744-8069-10-56 |
0.373 |
|
| 2014 |
Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27. PMID 24742127 DOI: 10.1186/1744-8069-10-27 |
0.749 |
|
| 2014 |
Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management. 47: 166-73. PMID 23742737 DOI: 10.1016/j.jpainsymman.2013.02.018 |
0.363 |
|
| 2013 |
Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 67: 94-109. PMID 23127915 DOI: 10.1016/j.phrs.2012.10.013 |
0.501 |
|
| 2012 |
Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, Hohmann AG. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CBâ‚‚ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Molecular Pain. 8: 71. PMID 22998838 DOI: 10.1186/1744-8069-8-71 |
0.491 |
|
| 2012 |
Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL, Zimmer A, Watanabe M, Mackie K, Katona I, Piomelli D, Hohmann AG. Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 9457-68. PMID 22787031 DOI: 10.1523/Jneurosci.0013-12.2012 |
0.423 |
|
| 2011 |
Sciolino NR, Zhou W, Hohmann AG. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 64: 226-34. PMID 21600985 DOI: 10.1016/J.Phrs.2011.04.010 |
0.774 |
|
| 2011 |
Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, Hohmann AG. Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain. 152: 1976-87. PMID 21550725 DOI: 10.1016/J.Pain.2011.03.038 |
0.4 |
|
| 2011 |
Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502. PMID 21382397 DOI: 10.1016/J.Pbb.2011.02.024 |
0.729 |
|
| 2011 |
Guindon J, Guijarro A, Piomelli D, Hohmann AG. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. British Journal of Pharmacology. 163: 1464-78. PMID 21198549 DOI: 10.1111/j.1476-5381.2010.01192.x |
0.447 |
|
| 2011 |
Sciolino N, Bortolato M, Eisenstein S, Fu J, Oveisi F, Hohmann A, Piomelli D. SOCIAL ISOLATION AND CHRONIC HANDLING ALTER ENDOCANNABINOID SIGNALING AND BEHAVIORAL REACTIVITY TO CONTEXT IN ADULT RATS (vol 168, pg 371, 2010) Neuroscience. 187: 103-103. DOI: 10.1016/J.Neuroscience.2011.04.071 |
0.739 |
|
| 2010 |
Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience. 13: 1265-70. PMID 20852626 DOI: 10.1038/Nn.2632 |
0.79 |
|
| 2010 |
Spradley JM, Guindon J, Hohmann AG. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 62: 249-58. PMID 20416378 DOI: 10.1016/j.phrs.2010.03.007 |
0.424 |
|
| 2010 |
Sciolino NR, Bortolato M, Eisenstein SA, Fu J, Oveisi F, Hohmann AG, Piomelli D. Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. Neuroscience. 168: 371-86. PMID 20394803 DOI: 10.1016/J.Neuroscience.2010.04.007 |
0.756 |
|
| 2010 |
Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57. PMID 20127295 DOI: 10.1208/S12248-009-9170-8 |
0.714 |
|
| 2010 |
Eisenstein SA, Clapper JR, Holmes PV, Piomelli D, Hohmann AG. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 61: 419-29. PMID 20044005 DOI: 10.1016/J.Phrs.2009.12.013 |
0.622 |
|
| 2009 |
Guindon J, Hohmann AG. The endocannabinoid system and pain. Cns & Neurological Disorders Drug Targets. 8: 403-21. PMID 19839937 DOI: 10.2174/187152709789824660 |
0.481 |
|
| 2009 |
Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 713-37. PMID 19789075 DOI: 10.1016/J.Nurt.2009.08.002 |
0.725 |
|
| 2009 |
Eisenstein SA, Holmes PV, Hohmann AG. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Synapse (New York, N.Y.). 63: 941-50. PMID 19593824 DOI: 10.1002/Syn.20679 |
0.623 |
|
| 2009 |
Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. The European Journal of Neuroscience. 29: 1964-78. PMID 19453631 DOI: 10.1111/J.1460-9568.2009.06751.X |
0.438 |
|
| 2009 |
Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews. 60: 255-66. PMID 19150370 DOI: 10.1016/j.brainresrev.2008.12.003 |
0.49 |
|
| 2008 |
Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91. PMID 18664590 DOI: 10.1124/Jpet.108.141994 |
0.765 |
|
| 2008 |
Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology. 200: 333-46. PMID 18545985 DOI: 10.1007/S00213-008-1209-5 |
0.422 |
|
| 2008 |
Guindon J, Hohmann AG. A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. British Journal of Pharmacology. 153: 1341-3. PMID 18297102 DOI: 10.1038/bjp.2008.41 |
0.321 |
|
| 2008 |
Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British Journal of Pharmacology. 153: 319-34. PMID 17994113 DOI: 10.1038/sj.bjp.0707531 |
0.496 |
|
| 2008 |
Suplita RL, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology. 54: 161-71. PMID 17714742 DOI: 10.1016/J.Neuropharm.2007.07.006 |
0.376 |
|
| 2007 |
Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77. PMID 17572696 DOI: 10.1038/Sj.Bjp.0707333 |
0.77 |
|
| 2007 |
Hohmann AG. Inhibitors of monoacylglycerol lipase as novel analgesics. British Journal of Pharmacology. 150: 673-5. PMID 17293886 DOI: 10.1038/sj.bjp.0707153 |
0.444 |
|
| 2007 |
Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. British Journal of Pharmacology. 150: 153-63. PMID 17160008 DOI: 10.1038/Sj.Bjp.0706984 |
0.476 |
|
| 2007 |
Rahn E, Hohmann A. 289 CANNABINOIDS SUPPRESS CHEMOTHERAPY-EVOKED PAINFUL PERIPHERAL NEUROPATHY THROUGH SPINAL SITES OF ACTION European Journal of Pain. 11: S128-S128. DOI: 10.1016/J.Ejpain.2007.03.304 |
0.727 |
|
| 2007 |
Hohmann A, Rahn E, Maxwell K, Zvonok A, Makriyannis A. 276 SELECTIVE ACTIVATION OF CANNABINOID CB2 RECEPTORS SUPPRESSES CHEMOTHERAPEUTIC NEUROPATHY EVOKED BY PACLITAXEL AND VINCRISTINE ADMINISTRATION European Journal of Pain. 11: S122-S122. DOI: 10.1016/J.Ejpain.2007.03.291 |
0.733 |
|
| 2007 |
Gutierrez T, Crystal J, Maxwell K, Zvonok A, Makriyannis A, Hohmann A. 272 SELF-ADMINISTRATION OF A CANNABINOID CB2 AGONIST IN AN ANIMAL MODEL OF NEUROPATHIC PAIN European Journal of Pain. 11: S120-S120. DOI: 10.1016/J.Ejpain.2007.03.287 |
0.387 |
|
| 2006 |
Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. The Aaps Journal. 8: E693-708. PMID 17233533 DOI: 10.1208/aapsj080479 |
0.418 |
|
| 2006 |
LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. The Journal of Pharmacology and Experimental Therapeutics. 319: 1051-61. PMID 16997973 DOI: 10.1124/Jpet.106.111385 |
0.398 |
|
| 2006 |
Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neuroscience Letters. 397: 180-4. PMID 16378681 DOI: 10.1016/j.neulet.2005.12.008 |
0.428 |
|
| 2006 |
Suplita RL, Gutierrez T, Fegley D, Piomelli D, Hohmann AG. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology. 50: 372-9. PMID 16316669 DOI: 10.1016/J.Neuropharm.2005.10.007 |
0.425 |
|
| 2005 |
Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handbook of Experimental Pharmacology. 509-54. PMID 16596786 DOI: 10.1007/3-540-26573-2-17 |
0.359 |
|
| 2005 |
Hohmann AG, Neely MH, Piña J, Nackley AG. Neonatal chronic hind paw inflammation alters sensitization to intradermal capsaicin in adult rats: a behavioral and immunocytochemical study. The Journal of Pain : Official Journal of the American Pain Society. 6: 798-808. PMID 16326368 DOI: 10.1016/j.jpain.2005.07.009 |
0.686 |
|
| 2005 |
Hohmann AG. A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain. 118: 3-5. PMID 16203094 DOI: 10.1016/j.pain.2005.07.007 |
0.375 |
|
| 2005 |
Suplita RL, Farthing JN, Gutierrez T, Hohmann AG. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology. 49: 1201-9. PMID 16129456 DOI: 10.1016/j.neuropharm.2005.07.007 |
0.445 |
|
| 2005 |
Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature. 435: 1108-12. PMID 15973410 DOI: 10.1038/Nature03658 |
0.608 |
|
| 2004 |
Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. Journal of Neurophysiology. 92: 3562-74. PMID 15317842 DOI: 10.1152/Jn.00886.2003 |
0.702 |
|
| 2004 |
Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. The Journal of Pharmacology and Experimental Therapeutics. 308: 446-53. PMID 14610224 DOI: 10.1124/Jpet.103.060079 |
0.507 |
|
| 2003 |
Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Research. 987: 176-85. PMID 14499961 DOI: 10.1016/S0006-8993(03)03324-9 |
0.694 |
|
| 2003 |
Crystal JD, Maxwell KW, Hohmann AG. Cannabinoid modulation of sensitivity to time. Behavioural Brain Research. 144: 57-66. PMID 12946595 DOI: 10.1016/S0166-4328(03)00062-7 |
0.373 |
|
| 2003 |
Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 119: 747-57. PMID 12809695 DOI: 10.1016/S0306-4522(03)00126-X |
0.733 |
|
| 2003 |
Nackley AG, Suplita RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 117: 659-70. PMID 12617970 DOI: 10.1016/S0306-4522(02)00870-9 |
0.717 |
|
| 2002 |
Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chemistry and Physics of Lipids. 121: 173-90. PMID 12505699 DOI: 10.1016/S0009-3084(02)00154-8 |
0.48 |
|
| 2000 |
Hohmann AG, Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse (New York, N.Y.). 37: 71-80. PMID 10842353 DOI: 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K |
0.518 |
|
| 1999 |
Hohmann AG, Tsou K, Walker JM. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica. 20: 1132-6. PMID 11216448 |
0.378 |
|
| 1999 |
Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sciences. 65: 665-73. PMID 10462067 DOI: 10.1016/S0024-3205(99)00289-1 |
0.368 |
|
| 1999 |
Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92: 1171-5. PMID 10426476 DOI: 10.1016/S0306-4522(99)00220-1 |
0.582 |
|
| 1999 |
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 96: 5780-5. PMID 10318961 DOI: 10.1073/Pnas.96.10.5780 |
0.597 |
|
| 1999 |
Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90: 923-31. PMID 10218792 DOI: 10.1016/S0306-4522(98)00524-7 |
0.523 |
|
| 1999 |
Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research. 822: 17-25. PMID 10082879 DOI: 10.1016/S0006-8993(98)01321-3 |
0.611 |
|
| 1999 |
Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. Journal of Neurophysiology. 81: 575-83. PMID 10036261 DOI: 10.1152/Jn.1999.81.2.575 |
0.358 |
|
| 1998 |
Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research. 813: 323-8. PMID 9838180 DOI: 10.1016/S0006-8993(98)01031-2 |
0.335 |
|
| 1998 |
Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neuroscience Letters. 252: 13-6. PMID 9756347 DOI: 10.1016/S0304-3940(98)00534-5 |
0.627 |
|
| 1996 |
Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker JM. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70: 791-8. PMID 10627219 |
0.435 |
|
| 1996 |
Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 6601-11. PMID 8815936 |
0.371 |
|
| 1992 |
Hohmann AG, Matsumoto RR, Hemstreet MK, Patrick SL, Margulies JE, Hammer RP, Walker JM. Effects of 1,3-di-o-tolylguanidine (DTG), a sigma ligand, on local cerebral glucose utilization in rat brain. Brain Research. 593: 265-73. PMID 1450934 DOI: 10.1016/0006-8993(92)91317-8 |
0.527 |
|
| Show low-probability matches. |
